Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Leukemia, Myeloid, Acute 12Myelodysplastic Syndromes 4Neoplasm Metastasis 3Melanoma 3Leukemia, Myelomonocytic, Chronic 3Breast Neoplasms 3Advanced Solid Tumor 3Recurrence 2Ovarian Neoplasms 2Lymphoma, B-Cell 2Leukemia, Monocytic, Acute 2Fallopian Tube Neoplasms 2Colonic Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Small Cell Lung Carcinoma 1Sarcoma, Synovial 1Sarcoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Papillomavirus Infections 1Non-Squamous Non-small Cell Lung Cancer 1Neoplasms 1Nasopharyngeal Carcinoma 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Multiple Myeloma 1Microsatellite Instability 1Lymphoma, Large B-Cell, Diffuse 1Leukemia, Myelomonocytic, Acute 1Leukemia, Basophilic, Acute 1Leukemia 1

Interventions

pelcitoclax 1osimertinib 1Injections 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × EGFR Positive Non-small Cell Lung Cancer × Injections × Clear all
NCT04001777 2025-10-01

A Study of APG-1252 Plus Osimertinib(AZD9291) in EGFR TKI Resistant NSCLC Patients

Ascentage Pharma Group Inc.

Phase 1 Active not recruiting
80 enrolled
Thoracic

EGFR Positive Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡